|
1) DiBardino DJ, McElhinney DB, Kaza AK, et al. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J Thorac Cardiovasc Surg. 2009; 137: 1334-41
|
|
|
|
2) Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004; 63: 496-502
|
|
|
|
|
|
3) Suda K, Raboisson MJ, Piette E, et al. Reversible atrioventricular block associated with closure of atrial septal defects using the Amplatzer device. J Am Coll Cardiol. 2004; 43: 1677-82
|
|
|
|
|
|
4) Carlson KM, Justino H, OʼBrien RE, et al. Transcatheter atrial septal defect closure: modified balloon sizing technique to avoid overstretching the defect and oversizing the Amplatzer septal occluder. Catheter Cardiovasc Interv. 2005; 66: 390-6
|
|
|
|
|
|
5) Thaler DE, Saver JL. Cryptogenic stroke and patent foramen ovale. Curr Opin Cardiol. 2008; 23: 537-44
|
|
|
|
|